Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK591122PMID: 37094055
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 19767-45-4
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of mesna during breastfeeding. Because it is used with toxic drugs such as ifosfamide, the manufacturer recommends to not breastfeed during treatment and for 1 week after the last dose of mesna or ifosfamide.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Mesna
CAS Registry Number
19767-45-4
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- [Assessment of the clinical usefulness of the preparation Mesna (Mucofluid, Mistabron) produced by UCB in treatment of certain laryngological diseases (author's transl)].[Otolaryngol Pol. 1980][Assessment of the clinical usefulness of the preparation Mesna (Mucofluid, Mistabron) produced by UCB in treatment of certain laryngological diseases (author's transl)].Semczuk B, Gołabek W, Kłos A, Horoch A, Siwiec H, Kupisz K. Otolaryngol Pol. 1980; 34(6):553-8.
- Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.[Pediatr Nephrol. 1994]Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.Mohrmann M, Ansorge S, Schönfeld B, Brandis M. Pediatr Nephrol. 1994 Aug; 8(4):458-65.
- In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.[J Cancer Res Clin Oncol. 1993]In vitro studies on interaction of 4-hydroperoxyifosfamide and 2-mercaptoethanesulphonate in malignant gliomas.Jäger AH, Bogdahn U, Apfel R, Pfeufer B, Dekant A. J Cancer Res Clin Oncol. 1993; 119(12):721-6.
- Review Ifosfamide.[Drugs and Lactation Database (...]Review Ifosfamide.. Drugs and Lactation Database (LactMed®). 2006
- Review Use of mesna to prevent ifosfamide-induced urotoxicity.[Support Care Cancer. 1998]Review Use of mesna to prevent ifosfamide-induced urotoxicity.Siu LL, Moore MJ. Support Care Cancer. 1998 Mar; 6(2):144-54.
- Mesna - Drugs and Lactation Database (LactMed®)Mesna - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...